Want to see QURE full AI Analyst Report?
QURE Stock Chart & Stats
$38.97
$0.25(0.64%)
At close: 4:00 PM EDT
$38.97
$0.25(0.64%)
Day’s Range― - ―
52-Week Range$8.73 - $71.50
Previous CloseN/A
Volume30.69K
Average Volume (3M)2.36M
Market Cap
$3.03B
Enterprise Value$2.79K
Total Cash (Recent Filing)$810.34M
Total Debt (Recent Filing)$62.83M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Nov 10, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.04
Shares Outstanding69,366,410
10 Day Avg. Volume1,073,170
30 Day Avg. Volume2,356,171
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.92
Price to Sales (P/S)85.48
P/FCF Ratio-7.73
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$65.70Price Target Upside68.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.9
Revenue Forecast (FY)$20.99M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress For AMT-130FDA agreement to accept the three-year AMT-130 analysis as the primary basis for an accelerated BLA, combined with RMAT/Breakthrough/Fast Track designations, materially shortens the pathway to market. This durable regulatory alignment reduces trial design risk and can accelerate potential commercial revenues and partner interest if confirmed.
Strengthened Liquidity From Equity RaiseA materially upsized public offering meaningfully bolsters cash resources, extending runway and enabling late‑stage development, regulatory filings and potential commercialization investments. Stronger funding reduces near-term financing pressure and supports execution of confirmatory trials and global regulatory strategies over months.
Positive Early AMT-260 Clinical SignalsEarly proof-of-concept in AMT‑260 showing large seizure reductions in several patients and acceptable safety demonstrates platform applicability beyond Huntington's. Durable benefit: positive signals expand the pipeline's commercial optionality, diversify future revenue streams, and increase the value of the AAV platform if replicated in larger cohorts.
Bears Say
Persistent Cash BurnSustained large negative operating and free cash flow implies ongoing dependency on external financing or partner milestones to fund operations. Over the medium term this creates execution risk if capital markets tighten and increases the likelihood of further dilution or constrained investment pacing for costly confirmatory trials and commercialization.
Very Small Revenue Base Vs Large LossesRevenue remains minimal relative to expenses, producing deep operating losses. This structural mismatch limits the company's ability to self-fund programs, makes results highly dependent on milestone and royalty timing, and raises sustainability concerns until a durable commercial product flow is established.
Capital Structure VolatilityHistorical swings to negative equity and prior high leverage indicate capital structure fragility. Even with current improvements, the company remains susceptible to earnings shocks or funding gaps; persistent losses and volatile equity position raise the structural risk of future dilutive financings or covenant pressures.
uniQure News
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $8.73 and its highest was $71.50 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $3.03B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Nov 10, 2026 which is in 99 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Jul 29, 2026. The company reported -$1.22 earnings per share for the quarter, missing the consensus estimate of -$0.822 by -$0.398.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.9.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 69,366,410 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$1.22 in its last earnings report, missing expectations of -$0.822. Following the earnings report the stock price went up 9.302%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in QURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
uniQure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.70 (68.59% Upside)
$65.70 (68.59% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 73%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 89.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $966.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bullish
Bullish news 91%
Bearish news 9%
Bearish news 9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
156.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
68.43%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated major positive clinical advances (notably strong 3‑year AMT‑130 efficacy, supportive Fabry and TLE data) and a strengthened balance sheet, but these were tempered by significant regulatory resistance from the FDA (recommendation for a sham‑controlled Phase III), safety‑related pauses/holds in two programs (AMT‑191 dosing pause and AMT‑162 hold), and a substantial year‑over‑year revenue decline. Management emphasized active regulatory engagement, continued data generation (4‑year AMT‑130 analysis) and pursuit of ex‑U.S. pathways and early access options, while acknowledging material uncertainty around Phase III design, cost and feasibility.View all QURE earnings summariesQURE Stock 12 Month Forecast
Average Price Target
$65.70
▲(68.59% Upside)
Technical Analysis
Ownership Overview
2.00% Insiders
12.11% Mutual Funds
1.38% Other Institutional Investors
76.53% Public Companies and
Individual Investors